Home » Eli Lilly Licenses Testosterone Drug From Acrux
Eli Lilly Licenses Testosterone Drug From Acrux
Eli Lilly & Co. has acquired the rights to market Acrux’s experimental testosterone
deficiency treatment worldwide in a deal potentially worth more than $335 million, the companies said.
Forbes
Forbes
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May